Johnson & Johnson Company (New Brunswick, NJ) agreed to buy the consumer healthcare business of Pfizer, Inc. (New York, NY) for $16.6 billion in cash.
Johnson & Johnson Company (J&J, New Brunswick, NJ, www.jnj.com) agreed tobuy the consumer healthcare business of Pfizer, Inc. (New York, NY, www.pfizer.com) for$16.6 billion in cash.
"This acquisition builds upon our broad base in health care productsand our leadership objectives in the consumer, pharmaceutical andmedical devices, and diagnostics markets," said William C. Weldon,J&J's chairman and CEO, in a company release. Pfizer's consumerhealthcare business includes personal care and over-the-counter (OTC)products such as "Zantac," "Sudafed," "Neosporin," and "Benadryl."Overall, the business posted 2005 sales of $3.9 billion. J&J alsowill acquire the US OTC switch rights to "Zyrtec" (cetirizine),Pfizer's once-a-day, nonsedating prescription antihistamine, uponpatent expiration.
Pfizer decided to sell the business following a review of the strategicoptions that the company had initiated in February. The deal isexpected to close by the end of 2006.
Pfizer also announced that during 2006 and 2007, it will purchase asmuch as $17 billion of the company's stock by using the net proceedsfrom the sale of its consumer healthcare business and cash from ongoingoperations.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.